SOURCE: Herborium Group, Inc.

December 14, 2010 08:30 ET

Herborium Commences Sales for AcnEase

SADDLE BROOK, NJ--(Marketwire - December 14, 2010) - Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced that it has started selling AcnEase®, its unique botanical acne and Rosacea treatment, on Sales on will commence later this week. This new distribution venue anticipates revenue of $350,000-plus by the end of 2011 and is part of Herborium's brand building efforts that will resonance in greater revenue and will further the company's goal to become the worldwide leader in Natural Acne Treatment and Preventative Therapy.

Conservative estimates suggest 50+ million people in the US alone suffer from acne and over 17 million from Rosacea symptoms. Currently the only class of FDA approved drugs to treat the cause of acne is the isotretinoins, represented by Hoffman La-Roche's product Accutane, which has recently been taken off the market due to the number of severe side effects, and the resultant class action suits.  AcnEase represents a safe and natural alternative for treatment of acne. 

"The opportunity for sales of AcnEase -- a safe, all natural botanical therapeutic on the Internet is extremely attractive," comments Dr. Agnes Olszewski, Herborium President and CEO. "Worldwide business-to-consumer (B2C) sales over the Internet are expected to reach $146 billion in 2010 while the potential value of e-commerce is estimated to be over $800 billion. In addition The Health Care Distribution Management Association (HDMA) in its 'HDMA Industry Profile and Health Care Fact Book' clearly indicated that one of the major forces shaping the industry today is the increasingly important role of the Internet in the distribution of healthcare products," adds Dr. Olszewski.

The new distribution arrangements are another example of Herborium's "Road-to-Market" Strategy  calling for revenue projections of $7.5 Million, as detailed ("Road-to-Market" Strategy), with the ultimate goal to eventually capture 1% of the Global Natural and Alternative Treatments Market.

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company's business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit and

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

Contact Information

  • Company Contact:
    Steve Haag
    Investor Relations
    (832) 413-6206